AUTHORS
Tiffany King, MD, phD, Venee Tubman, MD MMSc2, Samantha Olson3, Marian Michaels4, John Williams5, Jennifer Schuster6, Rangaraj Selvarangan7, Laura Stewart8, Natasha Halasa9, Janet Englund10, Eillen Klein11, Daniel Payne12, Geoffery Weinberg13, Peter Szilagyi14, Ayzsa Tannis15, Mary Staat16, Leila Sahni17, Julie Boom18
AFFILIATIONS
1 Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States
2 Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States
3 Centers for Disease Control and Prevention, Atlanta, Georgia, United States
4 UPMC Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
5 UPMC Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
6 Department of Pediatrics, University of Missouri - Kansas City, Kansas City, Missouri, United States
7 University of Missouri Kansas City, Children's Mercy Hospital, Kansas City, Missouri, United States
8 Vanderbilt University Medical Center, Nashville, Tennessee, United States
9 Vanderbilt University Medical Center, Nashville, Tennessee, United States
10 Seattle Children’s Research Institute, Seattle, Washington, United States
11 Seattle Children’s Research Institute, Seattle, Washington, United States
12 Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
13 University of California at Los Angeles, Los Angeles, California, United States
14 University of California at Los Angeles, Los Angeles, California, United States
15 Centers for Disease Control and Prevention, Atlanta, Georgia, United States
16 Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
17 Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States
18 Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States
ABSTRACT
Introduction: Acute chest syndrome (ACS), defined by new finding(s) on radiographic imaging with fever or respiratory symptoms, is a leading cause of hospitalization for children with sickle cell disease (cwSCD). While viral etiologies are estimated to account for more than half of ACS episodes in cwSCD, the relative contribution of specific viruses to ACS is poorly characterized. The New Vaccine Surveillance Network (NVSN) is a U.S. multicenter prospective surveillance platform comprising seven pediatric hospitals that enroll children presenting with fever or respiratory symptoms, perform molecular testing for respiratory viruses, and captures clinical outcome information across outpatient, urgent care, emergency departments and hospital settings. We analyzed enrolled cwSCD to identify specific viral associations with ACS.
Methods: We included cwSCD 2-17 years old enrolled in NVSN during 2016–2024 who presented to emergency departments or were hospitalized with acute respiratory illness. Respiratory viral infections were identified by RT-PCR from nasal swab specimens. ACS was determined by encounter specific ICD-10 discharge diagnosis codes for ACS and pneumonia. Demographic information, viral positivity and clinical outcomes were compared between cwSCD with and without ACS. Frequency of influenza vaccination and influenza antiviral use were assessed. We used mixed-effects multivariable logistic regression models to assess associations between virus detection (primary exposure) and ACS (primary outcome) adjusting for age, asthma, vaso-occlusive crisis (VOC) and bacteremia as fixed effects, with study site as random effects. Associations with severe ACS were assessed using similar exposure and covariates, with three separate models for severity outcomes: ICU admission, hypoxemia and use of respiratory support.
Results: During 2016–2024, 604 cwSCD were enrolled of whom 194 (32.1%) were hospitalized with ACS. Children who developed ACS were older (7.0 vs. 6.1 years, p<0.01), were more likely to have hypoxemia (16% v 10%, p=0.02), require respiratory support (13% v 6%, p<0.01) or require ICU admission (7% v 2%, p<0.01) by chi-squared analysis.
Viral detections were common, occurring in 55% (334/604) of cwSCD overall and in 58% (113/194) of ACS episodes. Among cwSCD, rhinovirus/enterovirus was the most common virus detected (16%, 92/580), followed by influenza viruses (13%, 75/596), SARS-CoV-2 (9.3%, 34/366). Influenza viruses were detected in over a third (36%, n=41/113) of children with virus-positive ACS and was the only virus occurring more frequently in those with ACS compared to non-ACS episodes (21% vs. 8.4%, p <0.01). Receipt of current season influenza vaccine was 52% overall, with no difference in vaccine uptake between cwSCD with and without influenza-positive ACS (46% vs. 35%, p=0.38). Oseltamivir was administered to 80% of influenza-positive children with no differences in antiviral administration between ACS and non-ACS episodes (88% vs. 70%, p=0.05).
In multivariable analyses, influenza virus detection and VOC were independently associated with ACS [OR 9.02 (95% CI: 4.10-19.8) and 18.0 (95% CI: 10.2-31.8), respectively]. Influenza was not associated with development of VOC or severe ACS episodes. Although detected in only 4.1% (8/194) of ACS cases, HMPV was associated with 9-fold greater odds of ICU admission [9.12 (95% CI:1.15-72.6)] and nearly 14-fold greater odds of respiratory support [13.9 (95% CI: 2.58-74.8)].
Conclusions: This multicenter study of cwSCD with respiratory illnesses found viral infections contributed to more than half of ACS episodes. Influenza was associated with ACS episodes, underscoring the importance of optimizing prevention through influenza vaccination and use of prompt antiviral treatment in hospitalized cwSCD with suspected or confirmed influenza. HMPV occurred less commonly in this cohort but was associated with severe ACS episodes requiring ICU admission and respiratory support. Further studies are needed to determine if other sickle cell related factors (i.e. hydroxyurea use) contribute to the development of ACS episodes associated with viral infections.
DISCLOSURES
Tiffany King, MD, phD: No relevant conflicts of interest to declare.